Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Subscribe To Our Newsletter & Stay Updated